MNKD / Mannkind Corporation: Ready For Your Biotech Portfolio

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 third quarter more_horizontal

Tyvaso DPI, a collaboration with United Therapeutics, diversifies MannKind's revenue streams and leverages its proprietary Technosphere technology, bo more_horizontal

There's nothing like an estimate-topping quarter to put some pep in a company. A big jump in royalty revenue was particularly notable. more_horizontal

MannKind Corporation (NASDAQ:MNKD ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Michael Castagna - Chief Executive more_horizontal

While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended June 2023, it could be wort more_horizontal

MannKind (MNKD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.1 more_horizontal

Shares of MannKind Corp. MNKD, +2.78% fell 1.5% premarket on Monday after the biopharma company said a fire at a German manufacturing facility may del more_horizontal

MannKind had a big jump in revenue year over year. The company has benefitted from its collaboration agreement with United Therapeutics. more_horizontal